SAN DIEGO and SUZHOU, China, March 06, 2025 — Adagene Inc. (Nasdaq: ADAG), a company focused on pioneering new antibody-based therapies, announced today that its Chairman, CEO, and President of R&D, Peter Luo, Ph.D., will be available for one-on-one meetings with investors and will present a company update at Leerink’s Global Healthcare Conference 2025. The conference will be held in Miami, Florida, from March 10-12.

Leerink’s Global Healthcare Conference 2025

  • Presentation Date: Wednesday, March 12
  • Presentation Time: 10:40-11:20 AM (Eastern Time)
  • Location: W South Beach

A recording of the presentation will be available on the company’s website in the section for at least 30 days.

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a clinical-stage biotechnology company utilizing its platform to advance the discovery and development of innovative antibody-based cancer immunotherapies. Adagene leverages computational biology and AI to engineer novel antibodies that address significant unmet needs in patient care worldwide. The company has established strategic collaborations with leading global partners, utilizing its SAFEbody® precision masking technology in a variety of cutting-edge scientific approaches.

Fueled by its proprietary Dynamic Precision Library (DPL) platform, which includes NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s pipeline is highly differentiated and features novel immunotherapy programs. The company’s SAFEbody technology is designed to improve the safety and tolerability of antibody therapeutics by using precision masking to shield the biologic therapy’s binding domain. Activation within the tumor microenvironment enables tumor-specific targeting of antibodies, minimizing off-target toxicity in healthy tissues.

Adagene’s leading clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a specific CTLA-4 epitope in regulatory T cells (Tregs) within the tumor microenvironment. ADG126 is currently undergoing phase 1b/2 clinical trials in combination with anti-PD-1 therapy, with a particular focus on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Clinical research has validated the SAFEbody platform, demonstrating its applicability to various antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.

For more information, please visit: .
Follow Adagene on , and .

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

Investor Contacts:

Raymond Tam
Adagene

Bruce Mackle
LifeSci Advisors